Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies - Arai, Heii; Suzuki, Hideo; Yoshiyama, Tamotsu (Current Alzheimer research, 2015)
Keywords: Aged; Aged, 80 and over; Alzheimer Disease - drug therapy; Amyloid beta-Peptides - immunology; Antibodies - administration & dosage; Cohort Studies; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunologic Factors - administration & dosage; Japan; Male; Middle Aged; Psychiatric Status Rating Scales; Recombinant Fusion Proteins - therapeutic use; Saponins - administration & dosage; Time Factors; Treatment Outcome; Japan